



Figure 1




= SOLID SUPPORT

R = TERMINAL PROTECTING GROUP
 FOR EXAMPLE:
 DIMETHOXYTRITYL (DMT)

(1) = CLEAVABLE LINKER
 (FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR
 INVERTED DEOXYABASIC SUCCINATE)
 (2) = CLEAVABLE LINKER
 (FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR
 INVERTED DEOXYABASIC SUCCINATE)



INVERTED DEOXYABASIC SUCCINATE
 LINKAGE



GLYCERYL SUCCINATE LINKAGE

Figure 2




Figure 3






Figure 4



POSITIONS (NN) CAN COMPRISE ANY NUCLEOTIDE, SUCH AS DEOXYNUCLEOTIDES
(eg. THYMIDINE) OR UNIVERSAL BASES
B = ABASIC, INVERTED ABASIC, INVERTED NUCLEOTIDE OR OTHER TERMINAL CAP
THAT IS OPTIONALLY PRESENT
L = GLYCERYL MOIETY THAT IS OPTIONALLY PRESENT
S = PHOSPHOROTHIOATE OR PHOSPHORODITHIOATE

Figure 5



lower case = 2'-O-Methyl or 2'-deoxy-2'-fluoro
italic lower case = 2'-deoxy-2'-fluoro
underline = 2'-O-methyl

ITALIC UPPER CASE = DEOXY
B = INVERTED DEOXYABASIC
L = GLYCERYL MOIETY OPTIONALLY PRESENT
S = PHOSPHOROTHIOATE OR
PHOSPHORODITHIOATE

Figure 6




Figure 9: Target site Selection using siRNA






Figure 10



R = O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl
 B = Independently any nucleotide base, either naturally occurring or chemically modified, or optionally H (abasic).

Figure 11: Modification Strategy



**Figure 12: Inhibition of VEGF-Induced Angiogenesis
 by siRNAs**




Figure 13: A375 24h 36B4 VEGFR1 mRNA Expression






Figure 14: Phosphorylated siNA constructs



Phosphates can be modified
as described herein



Asymmetric duplex
siNA



(n) = number of base
pairs (e.g. 3-18 bp)

**Figure 16: siNA Targeting VEGFR-1 Inhibits
VEGF-Induced Rat Corneal Angiogenesis**






Figure 17: Inhibition of Mouse CNV with anti-VEGFR-1 siNA (intraocular administration)

57% inhibition at 1.5 µg vs inverted control

66% inhibition at 0.5 µg vs saline



**Figure 18: Inhibition of Mouse CNV with
anti-VEGFR-1 siNA (periocular administration)**



**Figure 19: Inhibition of Mouse CNV with
 anti-VEGFR-1 siNA (periocular administration)**

